Methods of treating neurological diseases and disorders

Abstract

The present invention is directed to compositions and methods for modulating c-Rel-dependent cytokine production without materially altering the level of expression of NFκB and/or the amount of IκB. The present invention is also directed to screening for modulators of c-Rel activity as determined by assaying for altered subcellular localization of c-Rel but where the level of expression of NFκB and/or the amount of IκB is materially unaltered.

1 - 16 . (canceled) 
     
     
         17 . A method of treating dementia in a subject in need thereof, the method comprising administering to the subject a pharmaceutical composition comprising an amount of Compound 2: N-(3-methyl-benzylidene)-N′-[6-morpholin-4-yl-2-(2-pyridin-2-yl-ethoxy)-pyrimidin-4-yl]-hydrazine, or a pharmaceutically acceptable salt thereof. 
     
     
         18 . The method of  claim 17 , wherein the dementia is selected from the group consisting of AIDS dementia complex, senile dementia of Lewy body type, and dementia pugilistica. 
     
     
         19 . The method of  claim 18 , wherein the pharmaceutical composition is formulated for a route of administration selected from intravenous, intranasal, or oral. 
     
     
         20 . The method of  claim 19 , wherein the pharmaceutical composition is formulated for intravenous administration. 
     
     
         21 . The method of  claim 20 , wherein the amount of Compound 2 in the composition is from 1 to 50 mg per kilogram of the subject's body weight. 
     
     
         22 . The method of  claim 19 , wherein the pharmaceutical composition is formulated for intranasal administration. 
     
     
         23 . The method of  claim 22 , wherein the amount of Compound 2 in the composition is from 0.1 to 50 mg per kilogram of the subject's body weight. 
     
     
         24 . The method of  claim 19 , wherein the pharmaceutical composition is formulated for oral administration. 
     
     
         25 . The method of  claim 24 , wherein the pharmaceutical composition is a tablet, caplet, hard gelatin capsule, soft gelatin capsules, troche, dragee, dispersion, suspension, or solution. 
     
     
         26 . The method of  claim 24 , wherein the amount of Compound 2 in the composition is from 1 microgram to 500 milligrams per kilogram of the subject's body weight. 
     
     
         27 . The method of  claim 24 , wherein the pharmaceutical composition is a controlled release formulation. 
     
     
         28 . The method of  claim 17 , wherein the subject is human. 
     
     
         29 . The method of  claim 18 , wherein the subject is human.